New Delhi: For 2022, brokerage firm HDFC Securities has issued a call to buy these ten stocks – Aditya Birla Capital, Gail India, Hindustan Zinc, Ipca Labs, Mahindra & Mahindra, Max. Financial, Max Healthcare, State Bank of India, Tech Mahindra, Zee entertainment.Also Read – MapmyIndia IPO is listed on the stock market today. Direct link to check the share price here
Aditya Birla capital is the holding company for all financial services companies in the Aditya Birla Group. Also Read – Paytm Share Price: JM Financial is issuing a call to sell for shares with a target price of Rs 1,240
“The company is continuing its credible overhaul to bring consolidated rates of return closer to franchise potential over the next three years,” the brokerage firm said. Also Read – Covid Variant Omicron Is Unlikely To Affect FMCG, Pharmaceutical And Telecom Stocks
However, strong competition from competitors and newcomers and the deterioration in asset quality in the loan book due to the possible third wave of the Covid pandemic and the slowdown in the economy are major concerns for the stock.
Gas transportation and distribution companies GAIL plans to expand into petrochemicals, specialty chemicals and renewable energies to complement growth in its core business, the marketing and transportation of natural gas. She also intends to apply for new pipelines.
However, volatility in oil and gas prices, higher tariff cuts on existing pipelines, and regulatory changes could all impact the growth story in the near future, according to the brokerage firm.
Hindustan zinc is one of the world’s largest and India’s only integrated zinc-lead and silver manufacturers and the second largest zinc-lead miner in the world.
It is India’s largest primary zinc producer with a 77 percent share of the market including alloys and 80 percent without alloys.
“High operational efficiencies will be a low-cost zinc producer in the medium term, fueled by fully integrated operations and low-cost, high-grade zinc reserves, as well as access to most of the lead-zinc deposits in Rajasthan through long-term agreements with the Government of India,” she added.
for Ipca Labs, the brokerage house is positive in the Active Pharmaceutical Ingredients (API) segments due to strong volume growth in domestic formulations across all products, competitive cost and consistent quality.
The most important therapeutic segments include heart, pain, malaria, and anti-diabetic drugs, as well as anti-infectives. The company achieved 46 percent of its sales in FY21 on the domestic market and 54 percent on the international markets.
In case of Mahindra and Mahindra, the world’s largest tractor maker and the third largest car maker in India, the brokerage firm believes its product offering could help it outperform the entire automotive sector.
“M&M is aiming for a 10-fold increase in the farm equipment segment to drive growth in the medium term (through 2027),” it added.
However, chip scarcity, commodity price inflation, and the possibility of a third wave of Covid are the top risks to the company’s share price.
Comments are closed.